Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BenQ Medical TechnologyROCO:4116 +0.39%81 ROE % is 6.73% as of Dec. 2025, which is 0% above its 10-year median of 6.72. GuruFocus rates ROCO:4116 with a GF Score™ of 81/100 and a GF Value™ of NT$62.38 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 799 Medical Devices & Instruments companies, BenQ Medical Technology ranks better than 64.83% on this metric.
The historical rank and industry rank for BenQ Medical Technology's ROE % or its related term are showing as below:
ROCO:4116'
s ROE % Range Over the Past 10 Years
Min: 2.76 Med: 6.72 Max: 14.25
Current: 7.15
During the past 13 years, BenQ Medical Technology's highest ROE % was 14.25%. The lowest was 2.76%. And the median was 6.72%.
ROCO:4116's ROE % is ranked better than 64.83% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.54
vs ROCO:4116: 7.15
BenQ Medical Technology (ROCO:4116) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Dec. 2025) net income data. The Revenue data used here is four times the quarterly (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, BenQ Medical Technology's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BenQ Medical Technology ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BenQ Medical Technology's ROE % distribution charts can be found below:
* The bar in red indicates where BenQ Medical Technology's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
BenQ Medical Technology (ROCO:4116) has a ROE % of 6.73% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BenQ Medical Technology and its competitors. This is near median its historical median of 6.72. Over the past decade, BenQ Medical Technology's ROE % has ranged from 2.76 to 14.25. According to the industry distribution chart, BenQ Medical Technology ranks #281 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 35.2%.
Is BenQ Medical Technology's ROE % too high?
BenQ Medical Technology's current ROE % of 6.73% is near median its 10-year median of 6.72. Over the past 10 years, this metric has ranged from a low of 2.76 to a high of 14.25. The Medical Devices & Instruments industry median ROE % is 2.54. BenQ Medical Technology's value of 6.73% is 165% above this industry median. Based on the distribution chart, BenQ Medical Technology ranks #281 out of 799 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, BenQ Medical Technology has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BenQ Medical Technology's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, BenQ Medical Technology ranks #281 out of 799 companies for ROE %. This puts BenQ Medical Technology in the upper half of its industry. The industry median ROE % is 2.54. BenQ Medical Technology's value of 6.73% is 165% above this benchmark. Historically, BenQ Medical Technology's own ROE % has ranged from 2.76 to 14.25 over the past decade. While the company's 10-year median is 6.72 vs. the industry median of 2.54, BenQ Medical Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.54, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BenQ Medical Technology's current ROE % of 6.73% is 165% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BenQ Medical Technology and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BenQ Medical Technology's current ROE % is 6.73%, which is near median its own 10-year median of 6.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BenQ Medical Technology stock overvalued right now?
Based on GuruFocus' analysis, BenQ Medical Technology (ROCO:4116) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$62.38, compared to a current price of NT$38.60 — trading 38.1% below its estimated fair value. The current ROE % is 6.73%, which is near median its 10-year median of 6.72 and 165% above the Medical Devices & Instruments industry median of 2.54. BenQ Medical Technology's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For BenQ Medical Technology (ROCO:4116), the current ROE % is 6.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BenQ Medical Technology (ROCO:4116) Overvalued in 2026?
Based on GuruFocus' analysis, BenQ Medical Technology stock appears to be undervalued.
The current stock price of NT$38.60 is trading 38.1% below its estimated GF Value™ of NT$62.38.
GuruFocus considers BenQ Medical Technology to be Significantly Undervalued.
Key valuation signals for ROCO:4116:
ROE %: 6.73% (near median its 10-year median of 6.72)
GF Value™: NT$62.38 vs. price of NT$38.60 (38.1% below fair value)
Industry Position: 165% above the Medical Devices & Instruments median (#281 of 799)
No single metric tells the full story. See the ROCO:4116 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BenQ Medical Technology Corp is engaged in the manufacturing, assembly, maintenance, repair, and sales of professional medical equipment and consumables. Its products include surgical and gynecology tables, digital OR solutions, halogen and LED surgical lights, and medical imaging products, among others. The company's segment includes the R&D and Manufacturing Division and the Medical Services Division. The company generates the majority of its revenue from the Medical Services Division. Geographically, the company generates revenue from Taiwan, Mainland China, Indonesia, Thai, India, Colombia, and Others.
81GF Score
Get the complete analysis for ROCO:4116
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4116 has been successfully added to your 
